$CYCC
Cyclacel Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024015349 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $10.00K
YoY Change -37.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.237M
YoY Change -23.88%
% of Gross Profit
Research & Development $950.0K
YoY Change -81.86%
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change -66.67%
% of Gross Profit
Operating Expenses $2.187M
YoY Change -68.12%
Operating Profit -$2.177M
YoY Change -68.2%
Interest Expense $10.00K
YoY Change -93.51%
% of Operating Profit
Other Income/Expense, Net $10.00K
YoY Change -93.1%
Pretax Income -$2.167M
YoY Change -67.66%
Income Tax -$210.0K
% Of Pretax Income
Net Earnings -$1.957M
YoY Change -67.56%
Net Earnings / Revenue -19570.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.18
COMMON SHARES
Basic Shares Outstanding 6.287M 1.974M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.982M
YoY Change -49.83%
Cash & Equivalents $3.000M
Short-Term Investments
Other Short-Term Assets $309.0K
YoY Change -84.15%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.913M
YoY Change -55.79%
LONG-TERM ASSETS
Property, Plant & Equipment $4.000K
YoY Change -75.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $413.0K
YoY Change -67.2%
Total Long-Term Assets $468.0K
YoY Change -66.18%
TOTAL ASSETS
Total Short-Term Assets $4.913M
Total Long-Term Assets $468.0K
Total Assets $5.381M
YoY Change -56.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.126M
YoY Change 162.64%
Accrued Expenses $2.225M
YoY Change -66.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.351M
YoY Change -22.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.351M
Total Long-Term Liabilities $0.00
Total Liabilities $6.351M
YoY Change -22.55%
SHAREHOLDERS EQUITY
Retained Earnings -$436.4M
YoY Change 3.18%
Common Stock $2.000K
YoY Change -83.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$970.0K
YoY Change
Total Liabilities & Shareholders Equity $5.381M
YoY Change -56.94%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.957M
YoY Change -67.56%
Depreciation, Depletion And Amortization $1.000K
YoY Change -66.67%
Cash From Operating Activities -$3.067M
YoY Change -23.93%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K
YoY Change -98.04%
NET CHANGE
Cash From Operating Activities -3.067M
Cash From Investing Activities 0.000
Cash From Financing Activities -1.000K
Net Change In Cash -3.068M
YoY Change -24.79%
FREE CASH FLOW
Cash From Operating Activities -$3.067M
Capital Expenditures $0.00
Free Cash Flow -$3.067M
YoY Change -23.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Cyclacel Pharmaceuticals, Inc.
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1058892
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2152202
dei Entity Central Index Key
EntityCentralIndexKey
0001130166
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50626
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1707622
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Connell Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
517-7330
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6287205
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2982000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3378000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1931000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4066000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4913000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7444000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
51000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
93000
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
413000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1259000
CY2024Q3 us-gaap Assets
Assets
5381000
CY2023Q4 us-gaap Assets
Assets
8805000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4126000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3543000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2225000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4618000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6351000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8161000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37000
CY2024Q3 us-gaap Liabilities
Liabilities
6351000
CY2023Q4 us-gaap Liabilities
Liabilities
8198000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2152202
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1058892
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
436503000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
429796000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1033000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-908000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436442000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-428282000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-970000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
607000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5381000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8805000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
16000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
43000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
389000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
950000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5236000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5775000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15637000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1237000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1625000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4444000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4845000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2187000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6861000
us-gaap Operating Expenses
OperatingExpenses
10219000
us-gaap Operating Expenses
OperatingExpenses
20482000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2177000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6845000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10176000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20093000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
104000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-58000
CY2024Q3 cycc Investment Interest Income Expenses
InvestmentInterestIncomeExpenses
8000
CY2023Q3 cycc Investment Interest Income Expenses
InvestmentInterestIncomeExpenses
50000
cycc Investment Interest Income Expenses
InvestmentInterestIncomeExpenses
-18000
cycc Investment Interest Income Expenses
InvestmentInterestIncomeExpenses
243000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
50000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
145000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
40000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
235000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2167000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6700000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10136000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19858000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-210000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-668000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1976000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2574000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1957000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6032000
us-gaap Net Income Loss
NetIncomeLoss
-8160000
us-gaap Net Income Loss
NetIncomeLoss
-17284000
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
151000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1957000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6082000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8160000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17435000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1957000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6032000
us-gaap Net Income Loss
NetIncomeLoss
-8160000
us-gaap Net Income Loss
NetIncomeLoss
-17284000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-14586000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8571000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12967000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2050000
CY2024Q3 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
14468000
CY2023Q3 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-8642000
cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
12842000
cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
2198000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2075000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6103000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8285000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17136000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15939000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
401000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2023Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5263000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5171000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10578000
CY2023Q2 cycc Stock Issued During Period Value At Market Issuance Sales Agreement
StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement
1105000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
359000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2023Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5577000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5450000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5448000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6671000
CY2023Q3 cycc Increase In Carrying Amount Of Redeemable Common Stock
IncreaseInCarryingAmountOfRedeemableCommonStock
-3389000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
390000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2023Q3 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-8642000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8571000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6032000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4297000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
607000
CY2024Q1 cycc Stock Issued During Period Value Upon Conversion Of Pre Funded Warrants In Offering Issuance Costs
StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts
-80000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
203000
CY2024Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-2130000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2140000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2946000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2206000
CY2024Q2 cycc Stock Issued During Period Value Upon Conversion Of Pre Funded Warrants In Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingNetOfIssuanceCosts
6290000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
189000
CY2024Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
504000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-521000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3257000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
999000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
107000
CY2024Q3 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
14468000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-14586000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1957000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-970000
us-gaap Profit Loss
ProfitLoss
-8160000
us-gaap Profit Loss
ProfitLoss
-17284000
us-gaap Depreciation
Depreciation
5000
us-gaap Depreciation
Depreciation
23000
us-gaap Share Based Compensation
ShareBasedCompensation
499000
us-gaap Share Based Compensation
ShareBasedCompensation
1151000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-37000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-55000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3129000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3364000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-2070000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
599000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6634000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12202000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
6209000
cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
0
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
0
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
151000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6209000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-151000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-42000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-396000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12401000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3378000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18345000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2982000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5944000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
59000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
243000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
3715000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
4846000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
0
cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3000000.0
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-970000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
43000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
16000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
389000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11030759
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
475563
CY2024Q3 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
1248000
CY2023Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
2933000
CY2024Q3 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
374000
CY2023Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
792000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
309000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
341000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1931000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4066000
CY2024Q3 cycc Deposits Held By Related Party
DepositsHeldByRelatedParty
400000
CY2024Q3 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1616000
CY2023Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3668000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
277000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
570000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
332000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
380000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2225000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4618000
us-gaap Operating Lease Expense
OperatingLeaseExpense
57178
us-gaap Operating Lease Expense
OperatingLeaseExpense
55982
us-gaap Operating Lease Payments
OperatingLeasePayments
38058
us-gaap Operating Lease Payments
OperatingLeasePayments
55245
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
16000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
38000
CY2024Q3 cycc Lessee Operating Lease Liability Payments Due After Year Two
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
54000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
51000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
107000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
390000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
499000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1151000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y5M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M15D
CY2024Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8000000.0
CY2024Q2 cycc Cash Placement Fee Percentage
CashPlacementFeePercentage
0.070
CY2024Q2 cycc Management Fee Percentage To Aggregate Gross Proceeds
ManagementFeePercentageToAggregateGrossProceeds
0.010
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.06
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.06
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-015349-index-headers.html Edgar Link pending
0001558370-24-015349-index.html Edgar Link pending
0001558370-24-015349.txt Edgar Link pending
0001558370-24-015349-xbrl.zip Edgar Link pending
cycc-20240930.xsd Edgar Link pending
cycc-20240930x10q.htm Edgar Link pending
cycc-20240930x10q001.jpg Edgar Link pending
cycc-20240930x10q002.jpg Edgar Link pending
cycc-20240930xex31d1.htm Edgar Link pending
cycc-20240930xex31d2.htm Edgar Link pending
cycc-20240930xex32d1.htm Edgar Link pending
cycc-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
cycc-20240930x10q_htm.xml Edgar Link completed
cycc-20240930_cal.xml Edgar Link unprocessable
cycc-20240930_def.xml Edgar Link unprocessable
cycc-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cycc-20240930_lab.xml Edgar Link unprocessable